Development and validation of a model that predicts early death among cancer patients participating in phase i clinical trials investigating cytotoxics

Investigational New Drugs

Volumn 28, Issue 1, 2010, Pages 76-82

  Penel, Nicolas ^a,b   Delord, Jean Pierre ^c   Bonneterre, Marie Edith ^d   Bachelot, Thomas ^e   Ray Coquard, Isabelle ^e   Blay, Jean Yves ^e,f   Pascal, Laurent Benjamin ^a   Borel, Cécile ^c   Filleron, Thomas ^c   Adenis, Antoine ^a   Bonneterre, Jacques ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d Marcq en Baroeul ^*  (France)

^e CENTRE LÉON BÉRARD   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Albumin; Cancer; Decision making; Lymphopenia; Phase 1 clinical trial; Probability tree

Indexed keywords

ALBUMIN;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DEATH; FEMALE; HUMAN; LIFE EXPECTANCY; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROBABILITY; SOFT TISSUE SARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL DEATH; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 74149089423     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9224-x     Document Type: Article

References (34)

1. HW Grunwald 2007 Ethical and design issues of phase 1 clinical trials in cancer patients Cancer Invest 25 124 126 10.1080/07357900701225331 17453824 (Pubitemid 46598171)
2. R Kurzrock RS Benjamin 2005 Risks and benefits of phase 1 oncology trials, revisited N Engl J Med 352 930 932 10.1056/NEJMe058007 1:CAS:528:DC%2BD2MXhvFOhtLY%3D 15745986 (Pubitemid 40300304)
3. RO Dillman JA Koziol 1992 Phase I cancer trials: limitations and implications Mol Biother 4 117 121 10.1007/BF02171756 1:STN:280: DyaK3s%2FnsFCksw%3D%3D 1445664
4. MB Lipsett 1995 On the nature and ethics of phase I trials J Clin Oncol 13 1049 1051
5. TG Roberts BH Goulard L Squitieri, et al. 2004 JW. Trends in the risk and benefits to patients with cancer participating in phase 1 clinical trial JAMA 292 2130 2140 10.1001/jama.292.17.2130 1:CAS:528:DC%2BD2cXpsVKksbY%3D 15523074 (Pubitemid 39435104)
6. M Agrawal EJ Emanuel 2003 Ethics of phase 1 oncology studies: re-examining the arguments and data JAMA 290 1075 1082 10.1001/jama.290.8.1075 12941681 (Pubitemid 37430449)
7. CK Daugherty HJ Ratain E Grochowski, et al. 1995 Perceptions of cancer patients and their physicians involved in phase I trials J Clin Oncol 13 1062 1072 1:STN:280:DyaK2M3ls12htw%3D%3D 7738612
8. T Bachelot I Ray-Coquard G Catimel, et al. 2000 Multivariate analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials Ann Oncol 11 151 156 10.1023/A:1008368319526 1:STN:280:DC%2BD3c3it1ertw%3D%3D 10761748 (Pubitemid 30148727)
9. L Janisch R Mick RL Schilsky, et al. 1994 Prognostic factors for survival in patients treated in phase I clinical trials Cancer 74 1965 1973 10.1002/1097-0142(19941001)74:7<1965::AID-CNCR2820740723>3.0.CO;2-1 1:STN:280:DyaK2czmtlKltA%3D%3D 8082103 (Pubitemid 24301862)
10. N Yamamoto T Tamura M Fukuoka, et al. 1990 Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience Int J Oncol 15 737 741
11. C Han JP Braybrooke G Delplanque, et al. 2003 Comparison of prognostic factors in patients in phase 1 trials of cytotoxic drugs versus new non cytotoxic agents Br J Cancer 89 1166 1171 10.1038/sj.bjc.6601218 1:CAS:528:DC%2BD3sXns1Cmur4%3D 14520440 (Pubitemid 37363397)
12. HT Arkenau D Olmos JE Ang, et al. 2008 Clinical outcome and prognosis factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience Br J Cancer 98 1029 1033 10.1038/sj.bjc.6604218 1:CAS:528:DC%2BD1cXjtlGkt7k%3D 18349817
13. N Penel M Vanseymortier ME Bonneterre, et al. 2008 Prognostic factors among cancer patients with good performance status screened for phase I trials Invest New Drugs 26 53 58 10.1007/s10637-007-9088-x 17891337
14. I Ray-Coquard H Ghesquiere T Bachelot, et al. 2001 Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas Br J Cancer 85 816 822 10.1054/bjoc.2001.2011 1:CAS:528:DC%2BD3MXpt1KisLg%3D 11556830 (Pubitemid 33010546)
15. L Claude D Perol I Ray-Coquard, et al. 2005 Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma Radiother Oncol 76 334 339 10.1016/j.radonc.2005.06.004 16024123 (Pubitemid 41394285)
16. C Borg I Ray-Coquard I Philip, et al. 2004 CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients cancer Cancer 101 2675 2680 10.1002/cncr.20688 15503313 (Pubitemid 39532301)
17. JA Morris MJ Gardner 1988 Calculating confidence intervals for relative risks (odd ratios) and standardised ratios and rates BMJ 296 1313 1316 10.1136/bmj.296.6632.1313 1:STN:280:DyaL1c3lt1OjsQ%3D%3D 3133061
18. G Heinze M Schemper 2002 A solution to the problem of separation in logistic regression Stat Med 21 2409 2419 10.1002/sim.1047 12210625 (Pubitemid 34905459)
19. S Lemeshow DW Hosner 1982 A review of goodness of fit statistics for use in the development of logistic regression models Am J Epidemiol 115 92 106 1:STN:280:DyaL387htVyqtA%3D%3D 7055134
20. N Penel JC Neu S Clisant, et al. 2007 Risk factors for early cathter-related infections in cancer patients Cancer 110 1586 1592 10.1002/cncr.22942 17685401 (Pubitemid 47463074)
21. P Seve I Ray-Coquard V Trillet-Lenoir, et al. 2006 Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site Cancer 107 2668 2670 10.1002/cncr.22300 (Pubitemid 44845626)
22. RJ Coates WS Clark JW Eley, et al. 1990 Race, nutritional status, and survival from breast cancer J Natl Cancer Inst 82 1684 1692 10.1093/jnci/82.21. 1684 1:STN:280:DyaK3M%2FjvFektQ%3D%3D 2231755
23. SA Liu WC Tsai YK Wong, et al. 2006 Nutritional factors and survival of patients with oral cancer Head Neck 28 998 1007 10.1002/hed.20461 16906513 (Pubitemid 44630939)
24. M Van Glabbeke J Verweij PG Casali, et al. 2005 Initial and late resistance to imatinib in advanced gastrointestinal stroma tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer- Italian Sarcoma Group- Australasian Gastrointestinal Trials Group Study J Clin Oncol 23 5795 5804 10.1200/JCO.2005.11.601 16110036 (Pubitemid 46300176)
25. SR Walsh EJ Cook F Goulder 2005 Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer J Surg Oncol 91 181 184 10.1002/jso.20329 1:STN:280:DC%2BD2MvlvFCjtA%3D%3D 16118772 (Pubitemid 41254421)
26. N Penel C Fournier S Clisant, et al. 2004 Cause of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever Support Care Cancer 12 593 598 10.1007/s00520-004-0602-9 14770304
27. A Ribas LH Camacho G Lopez-Berestein, et al. 2005 Antimour activity in melanoma and anti-self response in a phase 1 trial with the anticytotoxic T-lymphocytes-associated antigen 4 monoclonal antibody CP-675,206 J Clin Oncol 23 8968 8977 10.1200/JCO.2005.01.109 1:CAS:528:DC%2BD28XktVCnsg%3D%3D 16204013 (Pubitemid 46217464)
28. OM Odenike RA Larson D Gajria, et al. 2008 Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde- thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia Invest New Drugs 26 233 239 10.1007/s10637-008- 9115-6 1:CAS:528:DC%2BD1cXkvFyjs7o%3D 18217206
29. E Chan D Mulkerin M Rothenberg, et al. 2008 A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas Invest New Drugs 26 241 247 10.1007/s10637-008-9118-3 1:CAS:528:DC%2BD1cXkvFyjsLc%3D 18217204
30. T Baetz E Einsenhauer L Siu, et al. 2007 A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours Invest New Drugs 25 217 225 10.1007/s10637-006-9021-8 1:CAS:528: DC%2BD2sXltlartrc%3D 17146732 (Pubitemid 46774697)
31. Sanborn SL, Gibbons J, Krishnamurthi S et al (2009) Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs (in press)
32. Michael M, Gibbs P, Smith R et al (2009) Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs (in press)
33. G Decoster G Stein EE Holdener 1990 Response and toxic deaths in phase I clinical trials Ann Oncol 1 175 181 1:STN:280:DyaK3M%2FosVaktQ%3D%3D 2148104
34. DD Von Hoff J Turner 1991 Response rates, duration of response and dose response effects in phase I studies Invest New Drugs 9 115 121